Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sudeep PharmaNSE:SUDEEPPHRM +4.49%21 Return-on-Tangible-Asset is 14.71% as of Jun. 2026, which is 29% below its 10-year median of 20.79. GuruFocus rates NSE:SUDEEPPHRM with a GF Score™ of 21/100. The stock has 8 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Sudeep Pharma ranks better than 88.99% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Sudeep Pharma's annualizedNet Income for the quarter that ended in Jun. 2026 was ₹1,622 Mil. Sudeep Pharma's average total tangible assets for the quarter that ended in Jun. 2026 was ₹0 Mil. Therefore, Sudeep Pharma's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 14.71%.
The historical rank and industry rank for Sudeep Pharma's Return-on-Tangible-Asset or its related term are showing as below:
NSE:SUDEEPPHRM'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 14.85 Med: 20.79 Max: 28.54
Current: 15.38
During the past 5 years, Sudeep Pharma's highest Return-on-Tangible-Asset was 28.54%. The lowest was 14.85%. And the median was 20.79%.
NSE:SUDEEPPHRM's Return-on-Tangible-Asset is ranked better than 88.99% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 2.82
vs NSE:SUDEEPPHRM: 15.38
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Sudeep Pharma Return-on-Tangible-Asset Related Terms
Sudeep Pharma Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Sudeep Pharma's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:SUDEEPPHRM vs ZTS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sudeep Pharma's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sudeep Pharma Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sudeep Pharma's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Sudeep Pharma's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 14.71% mean?
Sudeep Pharma (NSE:SUDEEPPHRM) has a Return-on-Tangible-Asset of 14.71% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Sudeep Pharma and its competitors. This is 29% below median its historical median of 20.79. Over the past decade, Sudeep Pharma's Return-on-Tangible-Asset has ranged from 14.85 to 28.54. According to the industry distribution chart, Sudeep Pharma ranks #111 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 11%.
Is Sudeep Pharma's Return-on-Tangible-Asset too high?
Sudeep Pharma's current Return-on-Tangible-Asset of 14.71% is 29% below median its 10-year median of 20.79. Over the past 10 years, this metric has ranged from a low of 14.85 to a high of 28.54. The Drug Manufacturers industry median Return-on-Tangible-Asset is 2.82. Sudeep Pharma's value of 14.71% is 421.6% above this industry median. Based on the distribution chart, Sudeep Pharma ranks #111 out of 1008 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sudeep Pharma has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Sudeep Pharma's Return-on-Tangible-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sudeep Pharma ranks #111 out of 1008 companies for Return-on-Tangible-Asset. This places Sudeep Pharma in the top 11% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 2.82. Sudeep Pharma's value of 14.71% is 421.6% above this benchmark. Historically, Sudeep Pharma's own Return-on-Tangible-Asset has ranged from 14.85 to 28.54 over the past decade. While the company's 10-year median is 20.79 vs. the industry median of 2.82, Sudeep Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 2.82, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sudeep Pharma's current Return-on-Tangible-Asset of 14.71% is 421.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Sudeep Pharma and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sudeep Pharma's current Return-on-Tangible-Asset is 14.71%, which is 29% below median its own 10-year median of 20.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sudeep Pharma stock overvalued right now?
Sudeep Pharma (NSE:SUDEEPPHRM) has a current Return-on-Tangible-Asset of 14.71%. The current Return-on-Tangible-Asset is 14.71%, which is 29% below median its 10-year median of 20.79 and 421.6% above the Drug Manufacturers industry median of 2.82. Sudeep Pharma's overall GF Score™ is 21/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Sudeep Pharma (NSE:SUDEEPPHRM), the current Return-on-Tangible-Asset is 14.71% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sudeep Pharma Ltd is a technology led manufacturer of excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries and is dedicated to contributing to the healthcare ecosystem. The company operates in two business verticals: Pharmaceutical, food, and nutrition. It focuses on providing refined, mineral-based single ingredients essential to the pharmaceutical, food, and nutrition industries and Specialty ingredients: It pertains manufacturing of specialty ingredients using advance technology solutions. The maximum revenue is generated from the Pharmaceutical, food, and nutrition segment. Geographically, it has presence in the United States, South America, Europe, the Middle East, Africa, and Asia-Pacific.
21GF Score
Get the complete analysis for NSE:SUDEEPPHRM
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SUDEEPPHRM has been successfully added to your 
